Division of Periodontics, Unesp - São Paulo State University, Institute of Science and Technology, São José dos Campos, São Paulo, Brazil.
Center for Clinical and Translational Research, The Forsyth Institute, Cambridge, MA, USA.
J Periodontol. 2020 Oct;91(10):1318-1327. doi: 10.1002/JPER.19-0613. Epub 2020 Jun 21.
Supplementation with omega-3 polyunsaturated fatty acids (ω-3 PUFA) and low-dose aspirin (ASA) have been proposed as a host modulation regimen to control chronic inflammatory diseases. The aim of this study was to investigate the clinical and immunological impact of orally administered ω-3 PUFA and ASA as adjuncts to periodontal debridement for the treatment of periodontitis in patients type 2 diabetes.
Seventy-five patients (n = 25/group) were randomly assigned to receive placebo and periodontal debridement (CG), ω-3 PUFA + ASA (3 g of fish oil/d + 100 mg ASA/d for 2 months) after periodontal debridement (test group [TG]1), or ω-3 PUFA + ASA (3 g of fish oil/d + 100 mg ASA/d for 2 months) before periodontal debridement (TG2). Periodontal parameters and GCF were collected at baseline (t0), 3 months after periodontal debridement and ω-3 PUFA + ASA or placebo for TG1 and CG (t1), after ω-3 PUFA + ASA (before periodontal debridement) for TG2 (t1), and 6 months after periodontal debridement (all groups) (t2). GCF was analyzed for cytokine levels by multiplex ELISA.
Ten patients (40%) in TG1 and nine patients (36%) in TG2 achieved the clinical endpoint for treatment (less than or equal to four sites with probing depth ≥ 5 mm), as opposed to four (16%) in CG. There was clinical attachment gain in moderate and deep pockets for TG1. IFN-γ and interleukin (IL)-8 levels decreased over time for both test groups. IL-6 levels were lower for TG1. HbA1c levels reduced for TG1.
Adjunctive ω-3 and ASA after periodontal debridement provides clinical and immunological benefits to the treatment of periodontitis in patients with type 2 diabetes.
补充欧米伽-3 多不饱和脂肪酸（ω-3 PUFA）和低剂量阿司匹林（ASA）已被提议作为一种宿主调节方案，以控制慢性炎症性疾病。本研究的目的是探讨口服 ω-3 PUFA 和 ASA 作为牙周清创术辅助治疗 2 型糖尿病患者牙周炎的临床和免疫影响。
75 名患者（n=25/组）被随机分配接受安慰剂和牙周清创术（CG）、牙周清创术后给予 ω-3 PUFA+ASA（3g 鱼油/d+100mg ASA/d 持续 2 个月）（试验组 [TG]1）或牙周清创术前给予 ω-3 PUFA+ASA（3g 鱼油/d+100mg ASA/d 持续 2 个月）（TG2）。在基线（t0）、牙周清创术后 3 个月和 TG1 和 CG 给予 ω-3 PUFA+ASA 或安慰剂时（t1）、TG2 给予 ω-3 PUFA+ASA（牙周清创术前）时（t1）以及牙周清创术后 6 个月（所有组）（t2）时收集牙周参数和龈沟液（GCF）。通过多重 ELISA 分析 GCF 中的细胞因子水平。
TG1 中有 10 名患者（40%）和 TG2 中有 9 名患者（36%）达到了治疗的临床终点（≤4 个位点的探诊深度≥5mm），而 CG 中只有 4 名患者（16%）达到了这一终点。TG1 中中度和深度牙周袋有临床附着体获得。两组的 IFN-γ和白细胞介素（IL）-8 水平随时间降低。TG1 的 IL-6 水平较低。TG1 的糖化血红蛋白水平降低。
牙周清创术后辅助使用 ω-3 和 ASA 可为 2 型糖尿病患者牙周炎的治疗提供临床和免疫益处。
